Related Experiment Video
Updated: Jun 13, 2025

A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate NMDA Receptor in Blood
Published on: January 9, 2018
N-methyl-D-aspartate receptor autoantibody levels in children with intractable and non-intractable epilepsy
Prastiya Indra Gunawan1, Nurani Widianti1, Riza Noviandi1
1Division of Neurology, Department of Child Health, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
Insights
Autoimmune N-methyl-D-aspartate-receptor (NMDAR) autoantibodies may play a role in childhood epilepsy. While levels were numerically higher in intractable cases, this study found no significant difference between intractable and non-intractable childhood epilepsy groups.
Area of Science:
- Neurology
- Immunology
- Pediatrics
Background:
- Intractable epilepsy in children is a significant neurological challenge.
- Autoimmune processes, particularly involving N-methyl-D-aspartate-receptor (NMDAR) autoantibodies, are implicated in epilepsy pathogenesis.
- Understanding the role of NMDAR autoantibodies is crucial for diagnosing and managing pediatric epilepsy.
Purpose of the Study:
- To compare N-methyl-D-aspartate-receptor (NMDAR) autoantibody levels in children with intractable epilepsy versus non-intractable epilepsy.
- To investigate the association between NMDAR autoantibody status and clinical characteristics in pediatric epilepsy patients.
Main Methods:
- A prospective analytical study was conducted with 75 pediatric epilepsy patients (1 month to 18 years).
- Patients were categorized into intractable and non-intractable epilepsy groups.
- N-methyl-D-aspartate-receptor (NMDAR) autoantibody levels were measured using ELISA, with statistical analysis via chi-squared and Wilcoxon-Mann-Whitney tests.
Main Results:
- N-methyl-D-aspartate-receptor (NMDAR) autoantibodies were detected in 41.3% of intractable epilepsy cases and 33.4% of non-intractable cases.
- A significant correlation was found between seizure frequency and NMDAR autoantibody positivity (P=0.002).
- No significant difference in NMDAR autoantibody levels was observed between the intractable and non-intractable epilepsy groups (P=0.157).
Conclusions:
- N-methyl-D-aspartate-receptor (NMDAR) autoantibody levels were numerically higher in children with intractable epilepsy.
- While not statistically significant, the trend suggests a potential role for NMDAR autoimmunity in severe pediatric epilepsy.
- Further research is warranted to elucidate the precise role of NMDAR autoantibodies in pediatric epilepsy.
Objective:
Intractable epilepsy in children is a prevalent neurological disorder that can pose serious risks. The involvement of the autoimmune system is a significant factor in the pathogenesis of the disease. The N-methyl-D-aspartate-receptor (NMDAR) is a glutamate receptor and ion channel present in neurons and is associated with the mechanism of autoimmune etiology in epilepsy. This study aims to compare the levels of NMDAR auto antibodies in children with intractable and non-intractable epilepsy.
Methods:
A prospective analytic study was conducted from June to September 2022. The study sample consisted of patients aged 1 month to 18 years diagnosed with epilepsy and receiving anti-seizure medication (ASM) therapy at Dr. Soetomo General Academic Hospital, Surabaya. The patients were divided into two groups, namely intractable epilepsy and non-intractable epilepsy. The NMDAR autoantibody levels were determined using enzyme-linked immunosorbent assay (ELISA). Statistical analysis employed the chi-squared and Wilcoxon-Mann-Whitney tests.
Results:
Seventy-five subjects were included in the study. Of these patients, 41.3 % with intractable epilepsy and 33.4 % with non-intractable epilepsy presented NMDAR auto antibodies. Analysis of the patient characteristics revealed a correlation between seizure frequency and NMDAR autoantibody positivity (P = 0.002) but not between the number of ASM and NMDAR autoantibody positivity (P > 0.05). The NMDAR autoantibody levels were not significantly different in children with intractable and non-intractable epilepsy (P = 0.157).
Conclusion:
The NMDAR autoantibody levels were numerically higher in children with intractable epilepsy compared with children with non-intractable epilepsy.
More Related Videos
10:19High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
Published on: November 23, 2013
08:20Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis
Published on: June 2, 2022
Related Concept Videos
Antiepileptic Drugs: Glutamate Antagonists
Arteries of the Lower Limbs
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...